{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:41:01Z","timestamp":1778744461100,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clnesp.2025.02.004","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:08:54Z","timestamp":1739898534000},"page":"474-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Low muscle mass as a poor prognostic factor in patients with advanced melanoma"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-422X","authenticated-orcid":false,"given":"Kohei","family":"Yamakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2482-6707","authenticated-orcid":false,"given":"Yusuke","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0584-0810","authenticated-orcid":false,"given":"Masahiro","family":"Aichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4785-5543","authenticated-orcid":false,"given":"Shingo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukie","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2025.02.004_bib1","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/jid.2008.423","article-title":"Increasing burden of melanoma in the United States","volume":"129","author":"Linos","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjd.15803","article-title":"Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients","volume":"178","author":"Teramoto","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-019-0607-8","article-title":"Targeted therapy and immunotherapy for melanoma in Japan","volume":"20","author":"Namikawa","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bjd.21241","article-title":"Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study","volume":"187","author":"Bai","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clnesp.2025.02.004_bib6","article-title":"Survival analysis of comprehensive treatment in Chinese patients with metastatic melanoma: a retrospective analysis","volume":"30","author":"Chen","year":"2024","journal-title":"Skin Res Technol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2022.111966","article-title":"Low skeletal muscle mass predicts poor prognosis for patients with stage III cervical cancer on concurrent chemoradiotherapy","volume":"109","author":"Aichi","year":"2023","journal-title":"Nutrition"},{"key":"10.1016\/j.clnesp.2025.02.004_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pan.2018.11.001","article-title":"Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy","volume":"19","author":"Kurita","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.clnesp.2025.02.004_bib9","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-09-1525","article-title":"Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer","volume":"15","author":"Tan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clnesp.2025.02.004_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2015.02.031","article-title":"Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma","volume":"63","author":"Fujiwara","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib11","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.clnu.2022.03.001","article-title":"Skeletal muscle is prognostic in resected stage III malignant melanoma","volume":"41","author":"Youn","year":"2022","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnesp.2025.02.004_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clnesp.2019.04.004","article-title":"Sarcopenia as an independent prognostic factor in patients with metastatic colorectal cancer: a retrospective evaluation","volume":"32","author":"da Cunha","year":"2019","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.clnesp.2025.02.004_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005323","article-title":"Sarcopenia shortens overall survival of patients with platinum-resistant recurrent ovarian cancer: inverse probability of treatment-weighting analysis","author":"Aichi","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clnesp.2025.02.004_bib14","article-title":"Impact of body composition on outcomes from anti-PD1\u00a0+\/- anti-CTLA-4 treatment in melanoma","volume":"8","author":"Young","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clnesp.2025.02.004_bib15","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41598-020-58498-2","article-title":"Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: a multicenter real-life study","volume":"10","author":"Cortellini","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnesp.2025.02.004_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/bjc.2016.431","article-title":"The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clnesp.2025.02.004_bib17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-017-0464-x","article-title":"Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients","volume":"35","author":"Heidelberger","year":"2017","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.clnesp.2025.02.004_bib18","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.21873\/anticanres.14528","article-title":"Higher BMI, but not sarcopenia, is associated with pembrolizumab-related toxicity in patients with advanced melanoma","volume":"40","author":"Hu","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clnesp.2025.02.004_bib19","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jcsm.12538","article-title":"Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma","volume":"11","author":"Chu","year":"2020","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnesp.2025.02.004_bib20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jjco\/hyab064","article-title":"Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)","volume":"51","author":"Yamazaki","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib21","doi-asserted-by":"crossref","first-page":"17967","DOI":"10.1002\/cam4.6438","article-title":"Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: a multi-center retrospective study in Japan (B-CHECK-RWD study)","volume":"12","author":"Namikawa","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clnesp.2025.02.004_bib22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jjco\/hyac034","article-title":"Overview of the ethical guidelines for medical and biological research involving human subjects in Japan","volume":"52","author":"Eba","year":"2022","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clnesp.2025.02.004_bib23","first-page":"53","article-title":"Adipose tissue volume determinations in women by computed tomography: technical considerations","volume":"10","author":"H Kvist","year":"1986","journal-title":"Int J Obes"},{"issue":"1","key":"10.1016\/j.clnesp.2025.02.004_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1152\/jappl.1998.85.1.115","article-title":"Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography","volume":"85","author":"Mitsiopoulos","year":"1985","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/hepr.12774","article-title":"Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria","volume":"46","author":"Nishikawa","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clnesp.2025.02.004_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.26641","article-title":"Long-term survival in patients with advanced melanoma","volume":"7","author":"van Not","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clnesp.2025.02.004_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25459","article-title":"Use of first-line immune checkpoint inhibitors and association with overall survival among patients with metastatic melanoma in the anti-PD-1 era","volume":"5","author":"Lamba","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clnesp.2025.02.004_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3389\/fonc.2020.00905","article-title":"Immune checkpoint inhibitors for advanced melanoma: experience at a single institution in Taiwan","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/1346-8138.15804","article-title":"Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma","volume":"48","author":"Uhara","year":"2021","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1186\/s12885-019-6030-5","article-title":"Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody","volume":"19","author":"Lee","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clnesp.2025.02.004_bib32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.clnu.2017.07.010","article-title":"Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review","volume":"37","author":"Pamoukdjian","year":"2018","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnesp.2025.02.004_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.699668","article-title":"Predictive value of skeletal muscle mass in recurrent\/metastatic head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors","volume":"11","author":"Arribas","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41430-017-0034-5","article-title":"Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging in a healthy Caucasian population","volume":"72","author":"van der Werf","year":"2018","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.clnesp.2025.02.004_bib35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/jgh3.12976","article-title":"Variation in skeletal muscle mass among patients with cirrhosis of different self-identified race\/ethnicity","volume":"7","author":"Ha","year":"2023","journal-title":"JGH Open"},{"key":"10.1016\/j.clnesp.2025.02.004_bib36","doi-asserted-by":"crossref","first-page":"E700","DOI":"10.1210\/jc.2011-2387","article-title":"Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia","volume":"97","author":"Burney","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clnesp.2025.02.004_bib37","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clnesp.2025.02.004_bib38","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(22)01654-3","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial","volume":"400","author":"Livingstone","year":"2022","journal-title":"Lancet"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545772500066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545772500066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T17:12:53Z","timestamp":1741972373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545772500066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":38,"alternative-id":["S240545772500066X"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2025.02.004","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low muscle mass as a poor prognostic factor in patients with advanced melanoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2025.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}